Category: Press Releases
-
Biodesix Enhances Access to Nodify Lung® Testing with Launch of New Blood Draw Method
Capillary device supports in-office blood collection in diverse practice locations without the need for venipuncture
-
Biodesix to Participate in Two Upcoming Investor Conferences in November
November 9, 2023 at 6:00 AM EST
-
Biodesix Announces Third Quarter 2023 Results and Highlights
Third quarter 2023 Lung Diagnostic test volume grew 60% over the comparable period in 2022 and 6% over second quarter of 2023;
-
Biodesix to Report Third Quarter 2023 Financial Results on November 7, 2023
October 24, 2023 at 6:00 AM EDT
-
Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual Meeting
Studies highlight the clinical utility and real-world impact of the Nodify CDT® and Nodify XL2® tests in managing both benign and malignant pulmonary nodules.
-
Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer
New data highlights two novel proteomic tests that support treatment decision making in patients with non-small cell lung cancer (NSCLC):
-
Biodesix to Participate in Two Upcoming Investor Conferences in September
September 5, 2023 at 6:00 AM EDT
-
Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer
Data demonstrates a 51% relative increase in the proportion of lung nodule biopsies diagnosing cancer
-
Biodesix Announces Second Quarter 2023 Results and Highlights
August 7, 2023 at 4:01 PM EDT
-
Biodesix Participates in Canaccord Genuity Annual Growth Conference
BOULDER, Colo.–(BUSINESS WIRE)– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1×1 investor meetings at the Canaccord Genuity 43rd Annual Growth Conference, which will be held from August 7-10, 2023.